BridgeMD
New treatment option for Neuroendocrine Tumors
Official title 68Ga-DOTA-TATE PET/CT Imaging in NETs
ClinicalTrials.gov ID: NCT04847505
What this study is testing
- What it's testing
- This clinical trial is a pragmatic study aiming to evaluate the innocuity/safety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine cancer patients. It is a single-center study, but with recruitment across all Canada.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Clinical requisition for a 68Ga-DOTA-TATE PET/CT signed by a referring doctor
- Patients with suspected or proven tumors expressing somatostatin receptors
- Informed consent by patient (or parents if patient is less than 18 years of age)
You likely can't join if
- \ Pregnancy (not an absolute exclusion). See below\ .
- Patient refusal to participate.
- Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.
- In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an...
- Severe medical condition involving the life of the pregnant woman and/or the fetus;
- Existing treatments that are ineffective or may present toxicity to the woman and/or fetus;
See the full eligibility criteria
- Clinical requisition for a 68Ga-DOTA-TATE PET/CT signed by a referring doctor
- Patients with suspected or proven tumors expressing somatostatin receptors
- Informed consent by patient (or parents if patient is less than 18 years of age)
- \ Pregnancy (not an absolute exclusion). See below\ .
- Patient refusal to participate.
- Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.
- In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an in-depth discussion with the treating physicians and the patient. In...
- Severe medical condition involving the life of the pregnant woman and/or the fetus;
- Existing treatments that are ineffective or may present toxicity to the woman and/or fetus;
- High clinical suspicion of a somatostatin receptor overexpressing tumour;
- Negative, indeterminate or contraindicated first-line imaging tests;
- Therapeutic gesture considered during pregnancy based on the results of the examination, which may include termination of pregnancy or premature delivery;
- Documented discussion with the treating team and the patient;
- Patient agrees.
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
- Sherbrooke, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada; Sherbrooke, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.